Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Chronic obstructive pulmonary disease (COPD) affects millions of people worldwide.

Obesity is commonly seen concomitantly with COPD.

Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and treatment of type-2 diabetes mellitus.

Who Took Part

According to the abstract, 40 people were involved.

At baseline and after 4, 20, 40, and 44 weeks, participants underwent pulmonary-function tests, 6-min walking test, and replied to a questionnaire regarding the clinical impact of COPD (COPD assessment test (CAT)-score).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The people were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the people nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Forced Expiratory Volume, Glucagon-Like Peptide-1 Receptor, Obesity, Pulmonary Disease, Chronic Obstructive and Quality of Life.

Author keywords: COPD, GLP-1 RA, inflammation and spirometry.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 40 people.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (International journal of chronic obstructive pulmonary disease), a journal based in New Zealand.

More context: the Glucagon compound page, all human trials.